Uncategorized
FDA’s oncology advisors vote against ‘new paradigm’ in AstraZeneca trial
FDA’s oncology advisors vote against ‘new paradigm’ in AstraZeneca trial
In its first meeting in about nine months, the FDA’s advisory committee of oncology experts voted 6-3 Thursday that a late-stage trial for AstraZeneca’s oral SERD camizestrant didn’t show a “clinically meaningful” benefit.
AstraZeneca touted … Read More